Drug Trial Radar · NCT02779738
A Study of Merestinib (LY2801653) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 2016
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of food on merestinib (standard meal and high-fat meal) compared to the fasted state. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In addition, the tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last approximately 28 days. Screening is required within 28 days prior to the start of the study.
Conditions
- Healthy
Interventions
MerestinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) for Merestinib for High-Fat Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
- Pharmacokinetics: Maximum Concentration (Cmax) for Merestinib for Standard Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
- Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for High-Fat Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
- Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for Standard Meal and Fasted StateTime frame: Predose through 120 hours after administration of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Inc
Daytona Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.